23 results
8-K
PCSA
Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
between the parties to the Purchase Agreement and not as statements of fact, and (ii) may apply standards of materiality in a way that is different from
8-K
EX-10.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
(or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) on the Closing Date … respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date
8-K
EX-10.2
PCSA
Processa Pharmaceuticals Inc
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
the Company is required to issue Shares under this Agreement, except those representations and warranties qualified by materiality or Material Adverse Effect … representations and warranties qualified by materiality or Material Adverse Effect, which representations and warranties shall be true and correct in all
8-K
EX-99.2
di4yl
9 Jan 14
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.1
pw4d23pw1hto4iz1l
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.1
whl4aacljs
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
qm8 8507f6m2g
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-1.1
zs67wq7g
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm